X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare GSK Pharma with Cadila Healthcare - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs CADILA HEALTHCARE - Comparison Results

GSK PHARMA    Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA CADILA HEALTHCARE GSK PHARMA/
CADILA HEALTHCARE
 
P/E (TTM) x 63.0 32.1 196.1% View Chart
P/BV x 10.1 6.0 169.4% View Chart
Dividend Yield % 1.3 0.8 158.8%  

Financials

 GSK PHARMA   CADILA HEALTHCARE
EQUITY SHARE DATA
    GSK PHARMA
Mar-17
CADILA HEALTHCARE
Mar-17
GSK PHARMA/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs3,838460 834.3%   
Low Rs2,637305 864.6%   
Sales per share (Unadj.) Rs354.292.1 384.5%  
Earnings per share (Unadj.) Rs39.814.8 268.4%  
Cash flow per share (Unadj.) Rs42.918.5 232.0%  
Dividends per share (Unadj.) Rs30.003.20 937.5%  
Dividend yield (eoy) %0.90.8 110.8%  
Book value per share (Unadj.) Rs236.968.0 348.5%  
Shares outstanding (eoy) m84.701,023.74 8.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x9.14.2 220.1%   
Avg P/E ratio x81.425.8 315.4%  
P/CF ratio (eoy) x75.520.7 364.9%  
Price / Book Value ratio x13.75.6 242.9%  
Dividend payout %75.421.6 349.3%   
Avg Mkt Cap Rs m274,216391,581 70.0%   
No. of employees `0004.716.9 27.9%   
Total wages/salary Rs m4,83015,002 32.2%   
Avg. sales/employee Rs Th6,387.05,594.5 114.2%   
Avg. wages/employee Rs Th1,028.3890.1 115.5%   
Avg. net profit/employee Rs Th717.1899.9 79.7%   
INCOME DATA
Net Sales Rs m30,00094,295 31.8%  
Other income Rs m7281,286 56.6%   
Total revenues Rs m30,72895,581 32.1%   
Gross profit Rs m4,19019,036 22.0%  
Depreciation Rs m2633,750 7.0%   
Interest Rs m0450 0.0%   
Profit before tax Rs m4,65516,122 28.9%   
Minority Interest Rs m0338 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m457-3 -15,233.3%   
Tax Rs m1,7441,289 135.3%   
Profit after tax Rs m3,36815,168 22.2%  
Gross profit margin %14.020.2 69.2%  
Effective tax rate %37.58.0 468.6%   
Net profit margin %11.216.1 69.8%  
BALANCE SHEET DATA
Current assets Rs m16,74260,223 27.8%   
Current liabilities Rs m7,20253,058 13.6%   
Net working cap to sales %31.87.6 418.5%  
Current ratio x2.31.1 204.8%  
Inventory Days Days5270 74.2%  
Debtors Days Days2188 23.6%  
Net fixed assets Rs m8,63572,984 11.8%   
Share capital Rs m8471,024 82.7%   
"Free" reserves Rs m19,22268,576 28.0%   
Net worth Rs m20,06969,600 28.8%   
Long term debt Rs m1024,684 0.0%   
Total assets Rs m30,038152,207 19.7%  
Interest coverage xNM36.8-  
Debt to equity ratio x00.4 0.1%  
Sales to assets ratio x1.00.6 161.2%   
Return on assets %11.210.3 109.3%  
Return on equity %16.821.8 77.0%  
Return on capital %25.517.9 142.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m52821,280 2.5%   
Fx outflow Rs m7,19310,874 66.1%   
Net fx Rs m-6,66510,406 -64.0%   
CASH FLOW
From Operations Rs m2,36013,495 17.5%  
From Investments Rs m3,008-29,103 -10.3%  
From Financial Activity Rs m-5,10823,158 -22.1%  
Net Cashflow Rs m2607,556 3.4%  

Share Holding

Indian Promoters % 0.0 74.8 -  
Foreign collaborators % 50.7 0.0 -  
Indian inst/Mut Fund % 10.2 8.3 122.9%  
FIIs % 23.8 5.9 403.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 11.0 140.0%  
Shareholders   102,036 44,069 231.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   FRESENIUS KABI ONCO.  DIVIS LABORATORIES  UNICHEM LAB  ALKEM LABORATORIES  AJANTA PHARMA  

Compare GSK PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Feb 23, 2018 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GSK PHARMA 8-QTR ANALYSIS

COMPARE GSK PHARMA WITH

MARKET STATS